Day One Biopharmaceuticals Inc (NASDAQ: DAWN) open the trading on Thursday, with great promise as it jumped 1.82% to $12.90, before settling in for the price of $12.67 at the close. Taking a more long-term approach, DAWN posted a 52-week range of $11.94-$18.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 0.00% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -84.59%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 67.85%. This publicly-traded company’s shares outstanding now amounts to $100.81 million, simultaneously with a float of $72.64 million. The organization now has a market capitalization sitting at $1.30 billion. At the time of writing, stock’s 50-day Moving Average stood at $13.98, while the 200-day Moving Average is $14.33.
Day One Biopharmaceuticals Inc (DAWN) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Day One Biopharmaceuticals Inc’s current insider ownership accounts for 27.97%, in contrast to 81.28% institutional ownership. According to the most recent insider trade that took place on Dec 10 ’24, this organization’s HEAD OF R&D sold 30,000 shares at the rate of 13.31, making the entire transaction reach 399,339 in total value, affecting insider ownership by 1,034,015. Preceding that transaction, on Nov 18 ’24, Company’s CHIEF EXECUTIVE OFFICER sold 10,554 for 13.21, making the whole transaction’s value amount to 139,420. This particular insider is now the holder of 108,377 in total.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Revenue Records
Day One Biopharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 67.85% and is forecasted to reach -1.14 in the upcoming year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Let’s observe the current performance indicators for Day One Biopharmaceuticals Inc (DAWN). It’s Quick Ratio in the last reported quarter now stands at 14.55. The Stock has managed to achieve an average true range (ATR) of 0.55. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 12.76.
In the same vein, DAWN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.01, a figure that is expected to reach -0.46 in the next quarter, and analysts are predicting that it will be -1.14 at the market close of one year from today.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
[Day One Biopharmaceuticals Inc, DAWN] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 64.52% While, its Average True Range was 0.52.
Raw Stochastic average of Day One Biopharmaceuticals Inc (DAWN) in the period of the previous 100 days is set at 16.99%, which indicates a major fall in contrast to 43.65% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 23.75% that was lower than 37.52% volatility it exhibited in the past 100-days period.
